Latest News

Add to Favorites Subscribe Share
newswise-fb-share-

Showing results

110 of 223212
Embargo will expire:
10-Dec-2019 9:00 AM EST
Released to reporters:
9-Dec-2019 4:35 PM EST

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 10-Dec-2019 9:00 AM EST

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Social and Behavioral Sciences

Embargo will expire:
12-Dec-2019 2:00 PM EST
Released to reporters:
9-Dec-2019 4:30 PM EST

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 12-Dec-2019 2:00 PM EST

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Research Results

Cornell certificate program develops understanding of beer selection

Cornell University

Cornell University's School of Hotel Administration has launched a Beer Essentials certificate program to help hospitality industry professionals develop the end-to-end understanding of beer production, tasting and selection necessary for establishing an effective beer program.

Channels: Alcohol and Alcoholism, All Journal News, Business Ethics, Education, Marketing,

Released:
9-Dec-2019 4:20 PM EST
Open in New Tab
Research Results
Newswise: Retrospective Analysis Shows Proton Therapy Well Tolerated in Patients Undergoing Breast Conserving Surgery

Retrospective Analysis Shows Proton Therapy Well Tolerated in Patients Undergoing Breast Conserving Surgery

Rutgers Cancer Institute of New Jersey

Investigators at Rutgers Cancer Institute of New Jersey conducted a retrospective review of patients treated with proton therapy following breast-conserving surgery and found acceptable toxicity rates along with good-to-excellent patient-reported cosmetic outcomes.

Channels: All Journal News, Cancer, Healthcare, Surgery, Women's Health,

Released:
9-Dec-2019 4:20 PM EST
Open in New Tab
Comment
Research Results
Embargo will expire:
10-Dec-2019 8:00 AM EST
Released to reporters:
9-Dec-2019 4:05 PM EST

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 10-Dec-2019 8:00 AM EST

The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application.
If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Expert Pitch
Newswise: Giving Common Antibiotic Before Radiation May Help Body Fight Cancer
  • Embargo expired:
    9-Dec-2019 4:00 PM EST

Giving Common Antibiotic Before Radiation May Help Body Fight Cancer

Perelman School of Medicine at the University of Pennsylvania

The antibiotic vancomycin alters the gut microbiome in a way that can help prime the immune system to more effectively attack tumor cells after radiation therapy

Channels: All Journal News, Cancer, Clinical Trials, Microbiome, Grant Funded News,

Released:
9-Dec-2019 12:00 AM EST
Open in New Tab
Comment
Research Results

Argonne’s debt to 2019 Nobel Prize for lithium-ion battery

Argonne National Laboratory

A roar of approval rang out at the U.S. Department of Energy’s (DOE’s) Argonne National Laboratory upon the announcement in October that John B. Goodenough, M. Stanley Whittingham and Akira Yoshino had won the 2019 Nobel Prize in Chemistry. On December 10th in Stockholm, they received this highly coveted prize for their major contributions to the invention of the lithium-ion battery, which is a long-standing major focus of research at Argonne.

Channels: All Journal News, DOE Science News, Energy, Engineering, Materials Science, Nanotechnology, Technology, DOE Science News,

Released:
9-Dec-2019 3:50 PM EST
Open in New Tab
Comment
Research Results
Newswise: Yale Cancer Center study suggests new approaches needed to manage ibrutinib-related toxicities in CLL patients
  • Embargo expired:
    9-Dec-2019 3:45 PM EST

Yale Cancer Center study suggests new approaches needed to manage ibrutinib-related toxicities in CLL patients

Yale Cancer Center

New findings by Yale Cancer Center (YCC) and Smilow Cancer Hospital researchers show that as the use of the drug ibrutinib climbs in patients with chronic lymphocytic leukemia (CLL), so do the rates of patients who stop taking the drug.

Channels: All Journal News, Blood, Cancer, Clinical Trials, Pharmaceuticals, Medical Meetings,

Released:
9-Dec-2019 10:50 AM EST
Open in New Tab
Comment
Research Results

Showing results

110 of 223212

Chat now!
2.60783